Genmab A (GMAB) Enterprise Value (2018 - 2026)
Genmab A (GMAB) reported Enterprise Value of -$1.5 billion for Q1 2026, down 4.18% on a YoY basis from -$1.6 billion in Q1 2025, and up 11.31% quarter-over-quarter from -$1.7 billion in Q4 2025.
Genmab A (GMAB) Enterprise Value (2018 - 2026) Analysis & Trends
Genmab A has reported Enterprise Value for 7 years, with the latest figure at -$1.5 billion in Q1 2026.
- For the quarter ending Q1 2026, Enterprise Value fell 4.18% year-over-year to -$1.5 billion; the trailing twelve-month figure through Mar 2026 stood at -$1.5 billion (down 4.18% YoY), and the FY2025 full-year result was -$1.7 billion, down 23.29% from the prior year.
- Enterprise Value for Q1 2026 stood at -$1.5 billion, up from -$1.7 billion in the prior quarter.
- The five-year high for Enterprise Value was -$995.0 million in Q3 2024, with the low at -$2.4 billion in Q4 2023.
- Historically, Enterprise Value has averaged -$1.7 billion across 4 years, with a median of -$1.6 billion in 2025.
- Annual changes were most pronounced in 2024 — Enterprise Value jumped 42.14% — and 2025, when it plunged 91.06%.
- Genmab A's Enterprise Value stood at -$2.4 billion in 2023, then surged by 42.14% to -$1.4 billion in 2024, then decreased by 23.29% to -$1.7 billion in 2025, then gained by 11.31% to -$1.5 billion in 2026.
- The last three Enterprise Value figures came in at -$1.5 billion (Q1 2026), -$1.7 billion (Q4 2025), and -$1.9 billion (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | -32.30 Mn |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | - |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | -4.14 Mn |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | -286.70 Mn |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | -2.77 Mn |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | -18.44 Mn |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | -7.20 Mn |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | -7.25 Bn |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | -584.73 Mn |
| 10 | Genmab A | 48.34 Bn | 46.82 Bn | 831.00 Mn | -1.52 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.52 Bn |
| Dec 31, 2025 | -1.72 Bn |
| Sep 30, 2025 | -1.90 Bn |
| Jun 30, 2025 | -1.50 Bn |
| Mar 31, 2025 | -1.46 Bn |
| Dec 31, 2024 | -1.39 Bn |
| Sep 30, 2024 | -995.00 Mn |
| Jun 30, 2024 | -2.21 Bn |
| Mar 31, 2024 | -2.33 Bn |
| Dec 31, 2023 | -2.40 Bn |
| Sep 30, 2020 | -6,517.00 |
| Dec 31, 2019 | -3,552.00 |
| Sep 30, 2019 | -4.64 Bn |
| Dec 31, 2018 | -896.07 Mn |